ALK inhibitors - Revision history

Michael: /* See also */

2019-12-31T02:19:34Z

Michael: /* See also */

2019-04-04T14:10:16Z

Michael at 23:58, 17 March 2019

2019-03-17T23:58:34Z

← Older revision		Revision as of 23:58, 17 March 2019
Line 2:		Line 2:

	*Alectinib.<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref><ref name=pmid29685646>{{Cite journal \| last1 = Pal \| first1 = SK. \| last2 = Bergerot \| first2 = P. \| last3 = Dizman \| first3 = N. \| last4 = Bergerot \| first4 = C. \| last5 = Adashek \| first5 = J. \| last6 = Madison \| first6 = R. \| last7 = Chung \| first7 = JH. \| last8 = Ali \| first8 = SM. \| last9 = Jones \| first9 = JO. \| title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. \| journal = Eur Urol \| volume = 74 \| issue = 1 \| pages = 124-128 \| month = 07 \| year = 2018 \| doi = 10.1016/j.eururo.2018.03.032 \| PMID = 29685646 }}</ref>		*Alectinib.<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref><ref name=pmid29685646>{{Cite journal \| last1 = Pal \| first1 = SK. \| last2 = Bergerot \| first2 = P. \| last3 = Dizman \| first3 = N. \| last4 = Bergerot \| first4 = C. \| last5 = Adashek \| first5 = J. \| last6 = Madison \| first6 = R. \| last7 = Chung \| first7 = JH. \| last8 = Ali \| first8 = SM. \| last9 = Jones \| first9 = JO. \| title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. \| journal = Eur Urol \| volume = 74 \| issue = 1 \| pages = 124-128 \| month = 07 \| year = 2018 \| doi = 10.1016/j.eururo.2018.03.032 \| PMID = 29685646 }}</ref>
	*Crizotinib.		*[[Crizotinib]].
	*Ceritinib.		*Ceritinib.
	*Brigatinib.		*Brigatinib.

Michael at 23:57, 17 March 2019

2019-03-17T23:57:41Z

← Older revision		Revision as of 23:57, 17 March 2019
Line 2:		Line 2:

	*Alectinib.<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref><ref name=pmid29685646>{{Cite journal \| last1 = Pal \| first1 = SK. \| last2 = Bergerot \| first2 = P. \| last3 = Dizman \| first3 = N. \| last4 = Bergerot \| first4 = C. \| last5 = Adashek \| first5 = J. \| last6 = Madison \| first6 = R. \| last7 = Chung \| first7 = JH. \| last8 = Ali \| first8 = SM. \| last9 = Jones \| first9 = JO. \| title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. \| journal = Eur Urol \| volume = 74 \| issue = 1 \| pages = 124-128 \| month = 07 \| year = 2018 \| doi = 10.1016/j.eururo.2018.03.032 \| PMID = 29685646 }}</ref>		*Alectinib.<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref><ref name=pmid29685646>{{Cite journal \| last1 = Pal \| first1 = SK. \| last2 = Bergerot \| first2 = P. \| last3 = Dizman \| first3 = N. \| last4 = Bergerot \| first4 = C. \| last5 = Adashek \| first5 = J. \| last6 = Madison \| first6 = R. \| last7 = Chung \| first7 = JH. \| last8 = Ali \| first8 = SM. \| last9 = Jones \| first9 = JO. \| title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. \| journal = Eur Urol \| volume = 74 \| issue = 1 \| pages = 124-128 \| month = 07 \| year = 2018 \| doi = 10.1016/j.eururo.2018.03.032 \| PMID = 29685646 }}</ref>
			*Crizotinib.
			*Ceritinib.
			*Brigatinib.
			*Lorlatinib.

	==See also==		==See also==

Michael at 23:55, 17 March 2019

2019-03-17T23:55:28Z

← Older revision		Revision as of 23:55, 17 March 2019
Line 1:		Line 1:
	'''ALK inhibitors''' are a group of drugs that act on tumours with ALK rearrangements.		'''ALK inhibitors''' are a group of drugs that act on tumours with ALK rearrangements.

	*Alectinib.<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref>		*Alectinib.<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref><ref name=pmid29685646>{{Cite journal \| last1 = Pal \| first1 = SK. \| last2 = Bergerot \| first2 = P. \| last3 = Dizman \| first3 = N. \| last4 = Bergerot \| first4 = C. \| last5 = Adashek \| first5 = J. \| last6 = Madison \| first6 = R. \| last7 = Chung \| first7 = JH. \| last8 = Ali \| first8 = SM. \| last9 = Jones \| first9 = JO. \| title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. \| journal = Eur Urol \| volume = 74 \| issue = 1 \| pages = 124-128 \| month = 07 \| year = 2018 \| doi = 10.1016/j.eururo.2018.03.032 \| PMID = 29685646 }}</ref>

	==See also==		==See also==

Michael: Created page with "'''ALK inhibitors''' are a group of drugs that act on tumours with ALK rearrangements. *Alectinib.{{Cite journal | last1 = Honda | first1 = K. | last2..."

2019-03-17T23:53:36Z

Created page with "'''ALK inhibitors''' are a group of drugs that act on tumours with ALK rearrangements. *Alectinib.<ref name=pmid30790150>{{Cite journal | last1 = Honda | first1 = K. | last2..."

New page

'''ALK inhibitors''' are a group of drugs that act on tumours with ALK rearrangements.

*Alectinib.<ref name=pmid30790150>{{Cite journal | last1 = Honda | first1 = K. | last2 = Kadowaki | first2 = S. | last3 = Kato | first3 = K. | last4 = Hanai | first4 = N. | last5 = Hasegawa | first5 = Y. | last6 = Yatabe | first6 = Y. | last7 = Muro | first7 = K. | title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. | journal = Invest New Drugs | volume = | issue = | pages = | month = Feb | year = 2019 | doi = 10.1007/s10637-019-00742-2 | PMID = 30790150 }}</ref>

==See also==
*[[Inflammatory myofibroblastic tumour]].
*[[ALK positive lung cancer]].

==References==
{{Reflist|1}}

[[Category:Drugs]]

← Older revision		Revision as of 02:19, 31 December 2019
Line 11:		Line 11:
	*[[ALK positive lung cancer]].		*[[ALK positive lung cancer]].
	*[[ALK translocation renal cell carcinoma]].		*[[ALK translocation renal cell carcinoma]].
			*[[ROS1-rearranged non-small cell lung carcinoma]].

	==References==		==References==

← Older revision		Revision as of 14:10, 4 April 2019
Line 10:		Line 10:
	*[[Inflammatory myofibroblastic tumour]].		*[[Inflammatory myofibroblastic tumour]].
	*[[ALK positive lung cancer]].		*[[ALK positive lung cancer]].
			*[[ALK translocation renal cell carcinoma]].

	==References==		==References==